Argenica Advances Late-Stage Stroke Trial with Clean FDA Safety Data and $6.35M Cash

Late-Stage Stroke Trial Design Nears Completion

Argenica Therapeutics (ASX:AGN) is advancing the design of a targeted late-stage clinical trial for its lead drug candidate ARG-007, known internationally as xaranetide, aiming at moderate to severe acute ischaemic stroke (AIS) patients. The company convened a global stroke Clinical Advisory Committee to refine the trial protocol, which will leverage precision medicine and AI-enabled diagnostics to optimise patient selection. This approach seeks to increase the likelihood of clinical success by focusing on those most likely to benefit.

Drug substance manufacturing is progressing with Corden Pharma in Europe, a critical step to ensure supply readiness for both clinical and potential commercial needs. Argenica expects to present the final trial design publicly in the third quarter of 2026 and submit the protocol synopsis to the US FDA for feedback shortly thereafter, marking a key milestone in regulatory alignment.

FDA Safety Assays Clear Major Regulatory Hurdle

Following an IND clinical hold from the FDA, Argenica completed three FDA-requested assays assessing ARG-007’s interaction with tenecteplase (TNK), cardiac safety via hERG assay, and genotoxicity through a mammalian cell gene mutation test. All assays returned clean and favourable safety profiles, addressing the FDA’s concerns and positioning the company to submit a comprehensive response to lift the clinical hold. This regulatory progress is pivotal to commencing the late-stage trial in the US.

Xaranetide Gains Global Recognition and Expands Potential Indications

The World Health Organisation confirmed the International Nonproprietary Name (INN) xaranetide for ARG-007 during the quarter, officially standardising the drug’s generic name for global regulatory and medical communities. This formal recognition supports Argenica’s communications and positioning in the neurotherapeutics market.

Adding to its clinical portfolio, xaranetide demonstrated significant neuroprotective effects in a preclinical concussion model conducted by Curtin University. A single low dose administered after repeated mild traumatic brain injury reduced neuroinflammation, oxidative stress, and axonal damage, with effects lasting up to 11 days post-injury. These findings complement prior evidence across moderate and severe traumatic brain injury models, suggesting broad therapeutic potential beyond stroke.

Clinical Data Presented at Major International Forums

Argenica showcased two abstracts from its Phase 2 ARG-007 trial at the European Stroke Organisation Conference in the Netherlands, highlighting safety and functional efficacy data to an international audience of stroke experts. The company also participated in BIO 2026 in San Diego, the world's largest biotech event, enhancing visibility and engagement with potential pharmaceutical partners ahead of the late-stage trial.

Cash Position Supports Continued Development

Argenica closed the quarter with $6.35 million in cash reserves, down from previous levels but sufficient to sustain preparatory activities for the late-stage AIS trial. Operating cash outflows were $1.605 million, primarily driven by research and development, including drug manufacturing and preclinical studies, as well as staff and corporate costs. The company benefits from non-dilutive funding exceeding $4 million from government grants and philanthropic sources, including the Australian Government’s Medical Research Future Fund.

Argenica is also preparing submissions for R&D tax incentive cash rebates for FY26, which will further support its financial runway. With regulatory milestones and trial design updates expected soon, the company is positioned to move into a critical phase of clinical development.